<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759406</url>
  </required_header>
  <id_info>
    <org_study_id>Mach-5</org_study_id>
    <nct_id>NCT02759406</nct_id>
  </id_info>
  <brief_title>Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study</brief_title>
  <official_title>Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palmaz Scientific</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Palmaz Scientific</source>
  <brief_summary>
    <textblock>
      This is a six (6) month, randomized, un-blinded, study to assess the safety and performance&#xD;
      of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent&#xD;
      System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss rate by Quantative/ Qualtative Cornary Angiographia</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total percentage of strut coverage by Optical Coherence Tomography analysis</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint is the occurrence of adverse events associated with the Investigational and comparator devices.</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>binary restenosis rate by Quantative/ Qualtative Cornary Angiographia</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Mach-5 Grooved</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>grooved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mach 5 Bare Metal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bare metal</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>coronary stent</intervention_name>
    <arm_group_label>Mach 5 Bare Metal</arm_group_label>
    <arm_group_label>Mach-5 Grooved</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients of any race greater than or equal to 18 years and of legal&#xD;
             consent&#xD;
&#xD;
          2. Patients must be willing to comply with the specified follow-up evaluation schedule&#xD;
&#xD;
          3. Patients who sign an informed consent (signed and dated) prior to any study-related&#xD;
             evaluation or procedure.&#xD;
&#xD;
          4. Patients who are willing to undergo a follow-up coronary angiogram and Endovascular&#xD;
             Imaging via Optical Coherence Tomography&#xD;
&#xD;
          5. Patients willing to be maintained on Aspirin and Clopidogrel bisulfate (Plavix) for&#xD;
             ninety (90) days post procedure.&#xD;
&#xD;
          6. Patients with a de novo coronary lesion causing angina and/or a positive function test&#xD;
&#xD;
          7. Patients who are eligible for percutaneous coronary interventions&#xD;
&#xD;
          8. Low risk NSTEMI defined as patients with ACS, unstable angina, positive cardiac&#xD;
             biomarkers and hemodynamically stable as assessed by the Investigator.&#xD;
&#xD;
          9. Patients with an acceptable risk for coronary bypass graft surgery (CABG)&#xD;
&#xD;
        Intra-Procedure Angiographic Criteria:&#xD;
&#xD;
          1. Single de novo target lesion &gt;50% diameter stenosis by angiography&#xD;
&#xD;
          2. Single target vessel 2.75 to 3.25 mm diameter&#xD;
&#xD;
          3. Lesion length of 14 to 20mm which is suitable for Palmaz Mach-5 Grooved Coronary Stent&#xD;
             System or the Palmaz Bare Metal Coronary Stent System.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or sensitivity to cobalt chromium (CoCr) alloy or its components.&#xD;
&#xD;
          2. Known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be&#xD;
             pre-treated adequately).&#xD;
&#xD;
          3. Patients unable to tolerate anticoagulant therapy or antiplatelet therapy.&#xD;
&#xD;
          4. History of bleeding or known coagulopathy.&#xD;
&#xD;
          5. Patients with thrombocytopenia and or neutropenia.&#xD;
&#xD;
          6. More than one stenosis &gt;50% in target vessel.&#xD;
&#xD;
          7. Lesion in aortic ostium.&#xD;
&#xD;
          8. Left main or LAD, CX lesions within 2-mm from the origin.&#xD;
&#xD;
          9. Ejection Fraction &lt;45%.&#xD;
&#xD;
         10. STEMI in evolution.&#xD;
&#xD;
         11. Disabling stroke within previous 30 days.&#xD;
&#xD;
         12. Patients currently enrolled in another Investigational device or drug study.&#xD;
&#xD;
         13. Previous enrollment in this study.&#xD;
&#xD;
         14. Women who are currently pregnant. (A negative pregnancy test for female subjects of&#xD;
             child bearing potential is required within 24 hours of procedure.)&#xD;
&#xD;
         15. Known or suspected active systemic infection.&#xD;
&#xD;
         16. Evidence of severe or uncontrolled systemic diseases, including chronic renal&#xD;
             insufficiency, or any condition which in the Investigator's opinion makes it&#xD;
             undesirable for the patient to participate in the trial or which would jeopardize&#xD;
             compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

